ASCO 2022: High-dose ifosfamide demonstrated as a standard of care for recurrent and primary refractory ewing sarcoma
Use of high-dose ifosfamide (Ifex) was found to be superior for treating recurrent and primary refractory…
Browsing: ASCO
ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast cancer with low HER2 expression levels
The use of trastuzumab deruxtecan (Enhertu), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared…
ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer
The use of panitumumab (Vectibix) plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic…
ASCO 2022: Autologous stem cell transplant showed improved progression-free survival in newly diagnosed multiple myeloma patients
The use of autologous stem cell transplant (ASCT) early in the course of treatment showed…
ASCO 2022: “New hope” for patients with blood cancers not responding to treatment
Peter Mac’s Associate Professor Michael Dickinson has presented new data from a trial of the…
Cancer groundshot: Access to proven treatments must parallel development of new therapies
Bishal Gyawali, Queen’s University, Ontario Where should investment be made today in order to save…
ASCO 2022: Cell-free DNA methylation used to predict chemo benefit in bladder cancer
A team of researchers from SWOG Cancer Research Network, a cancer clinical trials group funded…
ASCO 2022: Desmoplastic melanoma responds to PD-1 blockade immunotherapy
Tumours from desmoplastic melanoma, a rare cancer most commonly found on the head or neck,…
ASCO 2022: Next-generation immunotherapy drug shows continued promise in several advanced-stage cancers
Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or…
ASCO 2022: Immunotherapy drug combination is safe with promising results in glioblastoma
A novel combination of two experimental cancer immunotherapy agents along with an immune checkpoint blocker…